CLOSTRIDIOIDES DIFFICILE INFECTION
Clinical trials for CLOSTRIDIOIDES DIFFICILE INFECTION explained in plain language.
Never miss a new study
Get alerted when new CLOSTRIDIOIDES DIFFICILE INFECTION trials appear
Sign up with your email to follow new studies for CLOSTRIDIOIDES DIFFICILE INFECTION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Friendly bacteria capsules battle hospital superbugs
Disease control CompletedThis study tested whether giving capsules containing healthy gut bacteria from donors could help clear dangerous, drug-resistant germs from hospitalized patients who need long-term antibiotics. Forty-two patients received either the bacteria capsules or identical placebo pills. R…
Matched conditions: CLOSTRIDIOIDES DIFFICILE INFECTION
Phase: PHASE1, PHASE2 • Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Trial aims to stop deadly gut infection in High-Risk patients
Disease control CompletedThis study tested if adding the drug bezlotoxumab to standard care could prevent severe outcomes in patients with a dangerous C. difficile gut infection. It focused on 44 patients identified as high-risk using a special score based on their genes, blood tests, and gut bacteria. T…
Matched conditions: CLOSTRIDIOIDES DIFFICILE INFECTION
Phase: PHASE2 • Sponsor: Hellenic Institute for the Study of Sepsis • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
First human test for new gut infection drug shows early safety profile
Knowledge-focused CompletedThis early-stage study tested a single dose of an experimental drug called AZD5148, which is being developed to treat Clostridioides difficile (C. diff) infections. The main goal was to check if the drug was safe and to see how the body processes it in 16 healthy Japanese adults.…
Matched conditions: CLOSTRIDIOIDES DIFFICILE INFECTION
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:38 UTC